Binds Allergen Or Component Thereof Patents (Class 424/171.1)
-
Patent number: 12128079Abstract: Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.Type: GrantFiled: February 14, 2023Date of Patent: October 29, 2024Assignee: LPOXY THERAPEUTICS, INC.Inventor: Larry D. Sutton
-
Patent number: 11207241Abstract: The invention generally relates to prefilled disposable medication devices, method of making, and using to store, contain and deliver at least a diluent for allergenic extract and more particularly to a prefilled cartridge containing a diluent for allergenic extract for use with an injection pen for allergy treatments.Type: GrantFiled: March 17, 2014Date of Patent: December 28, 2021Inventor: Eric R. Daines
-
Patent number: 10935554Abstract: The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (SIT) in a patient. The present invention also provides for the measurement of allergen specific IgG and IgE in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen. The invention also provides methods for determining whether a patient suffering from an allergy is responsive to therapy with one or more therapeutic antibodies specific for the allergen.Type: GrantFiled: August 22, 2014Date of Patent: March 2, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: George D. Yancopoulos, Jamie Orengo
-
Patent number: 9388236Abstract: Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.Type: GrantFiled: April 25, 2013Date of Patent: July 12, 2016Assignee: Nestec SAInventors: George Wells, Ebenezer Satyaraj
-
Publication number: 20150017174Abstract: The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most within 60 minutes after administration of at least one tannin to a patient.Type: ApplicationFiled: December 19, 2012Publication date: January 15, 2015Inventor: Albert Missbichler
-
Publication number: 20140348935Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.Type: ApplicationFiled: April 28, 2014Publication date: November 27, 2014Inventor: Michael R. Simon
-
Patent number: 8883154Abstract: The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.Type: GrantFiled: December 14, 2009Date of Patent: November 11, 2014Assignee: The Board of Regents of the University of Texas SystemsInventors: Randall M. Goldblum, Terumi Midoro-Horiuti, Bo Ning, Ruby Tiwari
-
Patent number: 8715620Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: December 22, 2010Date of Patent: May 6, 2014Inventor: Ira Sanders
-
Patent number: 8597652Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.Type: GrantFiled: March 19, 2010Date of Patent: December 3, 2013Assignee: Genentech, Inc.Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
-
Publication number: 20130236475Abstract: Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicant: Nestec SAInventors: George Wells, Ebenzer Satyaraj
-
Publication number: 20130216591Abstract: The aim of this invention is to induce and maintain tolerance to specific antigens with IgA (Immunoglobulin A). It is theoretically likely that the major role of IgA is to induce and maintain tolerance because: it binds to epitopes(determinants) on the antigens; it does not mount destruction nor elimination of antigens; almost all antigens in the small intestine are not immunogens but tolerogens; and it is more important to induce tolerance rather than to stimulate immune responses in the small intestine. In other words, IgA is the inhibitor that suppresses IgM-, IgG- and IgE-mediated immune responses. Therefore, In order to induce tolerance to an antigen, it is theoretically effective to administrate the antigen and immunoglobulin A antibodies that are binding to the epitopes of the antigen.Type: ApplicationFiled: January 14, 2013Publication date: August 22, 2013Inventor: Haruyuki Sumimoto
-
Patent number: 8436119Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 10, 2013Date of Patent: May 7, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Patent number: 8404793Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 7, 2004Date of Patent: March 26, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Patent number: 8361460Abstract: The present invention provides a method for detecting food allergens, antibodies and antigens to prepare the antibodies. The antigens of this invention are a mixture comprising multiple native and/or heated food allergens that IgE antibodies of food-allergy patients recognize. The antibodies of this invention are prepared by immunizing animals with the above-mentioned antigens. The food allergen-detecting method of this invention relates to the above-mentioned antibodies. As the method can detect food allergens and food allergy-inducing foods, it can provide safety to food allergy patients.Type: GrantFiled: September 5, 2002Date of Patent: January 29, 2013Assignee: Nippon Meat Packers, Inc.Inventors: Fumiki Morimatsu, Yoshihisa Takahata, Takashi Matsumoto, Izumi Miyazawa, Muneshige Shimizu
-
Publication number: 20130011415Abstract: The invention relates to the field of antibodies. In particular the invention relates to milk-derived antigen specific antibodies for generating an adaptive immune response, methods of preparation, and uses thereof.Type: ApplicationFiled: January 14, 2011Publication date: January 10, 2013Inventor: Ruprecht Jules Joost van Neerven
-
Patent number: 8349292Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: November 23, 2011Date of Patent: January 8, 2013Inventor: Ira Sanders
-
Patent number: 8092781Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: December 22, 2010Date of Patent: January 10, 2012Inventor: Ira Sanders
-
Patent number: 8088360Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: December 22, 2010Date of Patent: January 3, 2012Inventor: Ira Sanders
-
Patent number: 8088361Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: December 22, 2010Date of Patent: January 3, 2012Inventor: Ira Sanders
-
Patent number: 7879340Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: November 20, 2003Date of Patent: February 1, 2011Inventor: Ira Sanders
-
Patent number: 7867715Abstract: The invention relates to an in vitro method of evaluating the immunological activity of a vaccine preparation in the form of a mixture of a molecular antigen and a carrier, wherein the mixture comprises a liquid phase and a solid phase, to which at least a part of the antigen is attached, the method comprising the steps of i) subjecting the vaccine to one or more measurements; and ii) using the measurement results to evaluate the immunological activity of the vaccine.Type: GrantFiled: July 28, 2004Date of Patent: January 11, 2011Assignee: ALK-Abello A/SInventors: Peter A Würtzen, Gitte Lund, Henrik H. Jacobi, Hans-Henrik Ipsen
-
Publication number: 20100143266Abstract: Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.Type: ApplicationFiled: July 9, 2008Publication date: June 10, 2010Inventors: Georg Wells, Ebenezar Satyaraj
-
Publication number: 20090324501Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: ApplicationFiled: June 11, 2007Publication date: December 31, 2009Applicant: Biomay AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renat Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Patent number: 7597889Abstract: Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and/or Fc?RIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.Type: GrantFiled: May 7, 1999Date of Patent: October 6, 2009Assignee: Cambridge Enterprise LimitedInventors: Kathryn Lesley Armour, Michael Ronald Clark, Lorna McLeod Williamson
-
Publication number: 20090117131Abstract: The present invention provides a pharmaceutical composition for preventing or treating allergic diseases comprising histamine and allergen-specific antibody as active ingredients. Also, the present invention provides a use of the above composition for the manufacture of medicament for preventing or treating allergic diseases. Further, the present invention provides a method of preventing or treating allergic diseases which comprises administrating the above pharmaceutical composition to a mammal. When the pharmaceutical composition of the present invention is administered to a mammal, a specific allergic immune response (hypersensitive immune response) to antigen inducing allergic reaction (allergen) that can not be effectively controlled by current standard pharmacological treatments can be effectively suppressed.Type: ApplicationFiled: March 20, 2007Publication date: May 7, 2009Inventors: Sook-Yeong Jeon, Dong Ho Nahm
-
Publication number: 20090104208Abstract: A polypeptide comprising an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or comprising at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: April 27, 2007Publication date: April 23, 2009Applicant: BIOMAY AGInventors: Rudolf Valenta, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20090035319Abstract: The present invention relates to antibodies and related molecules that specifically bind to C3a Receptor. Such antibodies have uses, for example, in the prevention and treatment of asthma, allergy, and other related inflammatory and immune disorders. The invention also relates to nucleic acid molecules encoding anti-C3a Receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to C3a Receptor.Type: ApplicationFiled: September 15, 2008Publication date: February 5, 2009Applicant: Human Genome Sciences, Inc.Inventor: Craig A. Rosen
-
Publication number: 20080254041Abstract: The present invention relates to a method for selecting one or more immunotherapeutic preparation having improved properties as a vaccine against a target antigen, said method comprising raising antibodies against a group of candidate preparations and selecting one or more preparations which produces antibodies having higher affinity against the target antigen than does anti-bodies raised against at least one other preparation from the group. More particularly it relates to the need to provide recombinant allergens (Bet V 1) for SIT which have been modified by protein engineering.Type: ApplicationFiled: September 10, 2004Publication date: October 16, 2008Applicant: Novozymes A/SInventors: Steffen Ernst, Charlotte Georgi Jakobsen, Erwin Ludo Roggen
-
Publication number: 20080166360Abstract: A purified nucleic acid molecule comprising a nucleotide sequence coding for allergen Dac g 5 having amino acid sequence SEQ ID NO. 2, a derivative or a fragment thereof.Type: ApplicationFiled: September 13, 2007Publication date: July 10, 2008Applicants: Seita Groupe Altadis, a French corporation, Stallergenes, a French corporationInventors: Ronald van Ree, Erica Van Oort, Caroline Bonneau, Loic Faye, Veronique Gomord
-
Patent number: 7247441Abstract: The invention relates to polypeptides made of mannitol-dehydrogenase of Cladosporium herbarum and Alternaria alternata nucleic acids coding therefor and the use thereof in diagnosis and therapy.Type: GrantFiled: March 19, 2003Date of Patent: July 24, 2007Assignee: Biomay Produktions- Und Handels-Aktienge SellschaftInventors: Birgit Simon-Nobbe, Peter Schneider, Ursula Denk, Verena Wally, Klaus Richter, Christian Radauer, Markus Teige, Christof Ebner, Michael Breitenbach
-
Patent number: 7087425Abstract: The invention provides methods and compositions for purifying protozoan oocysts. In particular embodiments, the oocysts are Eimeria oocysts. The methods comprise contacting a composition comprising fecal material and protozoan oocysts with polysaccharidase under conditions sufficient to reduce the amount of fecal material in the composition.Type: GrantFiled: March 29, 2005Date of Patent: August 8, 2006Assignee: Embrex, Inc.Inventors: James E. Hutchins, Robert C. Tuttle
-
Patent number: 6914129Abstract: The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.Type: GrantFiled: August 8, 2001Date of Patent: July 5, 2005Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 6849259Abstract: A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.Type: GrantFiled: May 25, 2001Date of Patent: February 1, 2005Assignee: Symphogen A/SInventors: John S. Haurum, Kirsten Drejer, Ulrik Gregers Winther Morch
-
Patent number: 6639054Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: GrantFiled: January 5, 2001Date of Patent: October 28, 2003Assignee: Monsanto Technology LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Patent number: 6558961Abstract: Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the individual are provided.Type: GrantFiled: September 3, 1999Date of Patent: May 6, 2003Assignee: PowderJect Research LimitedInventors: David F. Sarphie, Lee K. Roberts, Deborah L. Fuller
-
Publication number: 20020054878Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: ApplicationFiled: August 1, 2001Publication date: May 9, 2002Applicant: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Publication number: 20020009453Abstract: A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector. The allergen may be an allergen of house dust mites, e.g. Dermatophagoides farinae or D. pteronyssimus; dander from cat, dog or horse; tree pollen, e.g.Type: ApplicationFiled: May 25, 2001Publication date: January 24, 2002Applicant: Symphogen A/SInventors: John S. Haurum, Kirsten Drejer, Ulrik Gregers Winther Morch
-
Publication number: 20020009452Abstract: Disclosed is a method for altering undesirable immune responses by identifying mutant polypeptides that exhibit less of an undesirable immune response while retaining one or more desired characteristics. Such polypeptides are safer and can be more efficacious when introduced into a human, other mammal, or other animal. Either the altered immune response or a surrogate for the immune response, referred to as a measurable immune characteristic, can be assessed in the method. Generally, the measurable immune characteristic can itself be an undesirable immune response, the measurable immune characteristic can be involved in an undesirable immune response, and/or an undesirable immune response can be mediated by the measurable immune characteristic.Type: ApplicationFiled: February 10, 1999Publication date: January 24, 2002Inventor: MICHAEL CAPLAN
-
Publication number: 20010006944Abstract: The invention involves methods and materials for treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves administrating an antifungal agent such that it contact mucus in an amount, at a frequency, and for a duration effective to prevent, reduce, or eliminate non-invasive fungus-induced rhinosinusitis. This invention also provides methods and materials for diagnosing non-invasive fungus-induced rhinosinusitis and culturing non-invasive fungus from a mammalian mucus sample as well as specific antifungal formulations and medical devices for treating and preventing non-invasive fungus-induced rhinosinusitis. In addition, the invention provides methods and materials for treating and preventing other non-invasive fungus-induced mucositis conditions such as chronic otitis media, chronic colitis, and Crohn's disease. Further, the invention involves methods and materials for treating and preventing chronic asthma symptoms.Type: ApplicationFiled: October 22, 1998Publication date: July 5, 2001Inventor: JENS PONIKAU
-
Patent number: 6200565Abstract: The present invention is directed to methods of treating autoimmune sensorineural hearing loss in a patient by orally administering a human immunoglobulin preparation to the patient.Type: GrantFiled: May 7, 1999Date of Patent: March 13, 2001Assignee: Research Corporation Technologies, Inc.Inventor: Richard H. Weisbart